Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

Market Cap	36.95B
Revenue (ttm)	3.72B
Net Income (ttm)	476.19M
Shares Out	1.11B
EPS (ttm)	0.43
PE Ratio	77.10
Forward PE	58.31
Dividend	0.27 (0.78%)
Ex-Dividend Date	Jan 24, 2025

Volume	4,988,035
Average Volume	6,192,768
Open	30.18
Previous Close	34.41
Day's Range	30.18 - 34.80
52-Week Range	24.32 - 40.66
Beta	0.11
RSI	62.56
Earnings Date	Apr 12, 2025

About SHE:002653

Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular. The company was formerly known as Xizang Haisco Pharmaceut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 5,448
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2023, SHE:002653's revenue was 3.36 billion, an increase of 11.27% compared to the previous year's 3.02 billion. Earnings were 295.11 million, an increase of 6.51%.